Lyra Therapeutics, Inc. has announced a definitive agreement to sell 423,372 shares of common stock and associated private placement warrants through a registered direct offering priced at $11.81 per ...
LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, ...
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered ...
60 Degrees Pharmaceuticals closed a direct stock offering, raising approximately $1.075 million for working capital and corporate purposes. 60 Degrees Pharmaceuticals, Inc. has completed a registered ...
Largo Inc. (“Largo” or the “Company”) (TSX: LGO) (NASDAQ: LGO) is pleased to announce further details in connection with the binding term sheet entered into with the senior lenders (“Lenders”) to ...
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL) CRANFORD, N.J., Dec. 9, 2025 /PRNewswire/ -- Citius ...
CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results